New hope for advanced liver cancer: drug combo shows promise
NCT ID NCT07192848
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs (adebrelimab and apatinib) in people with advanced liver cancer that has worsened after prior treatment. The goal is to see if the combination can shrink tumors. About 47 adults will receive the drugs intravenously and orally every three weeks. The study is not yet recruiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA NON-RESECTABLE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Shenzhen, Guangdong, 518116, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new imaging agent could tell doctors which liver cancers will resist immunotherapy
- Can adding a fourth drug shrink large liver tumors that invade the portal vein?
- Can a Four-Drug cocktail tame inoperable liver cancer?
- Chemo-loaded microspheres aim to starve liver tumors from within
- New combo therapy aims to stop liver cancer in its tracks
- New combo therapy aims to shrink liver tumors in Hard-to-Treat patients